1. Home
  2. DMA vs XLO Comparison

DMA vs XLO Comparison

Compare DMA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destra Multi-Alternative Fund

DMA

Destra Multi-Alternative Fund

N/A

Current Price

$7.06

Market Cap

64.3M

Sector

Finance

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$8.60

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DMA
XLO
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.3M
56.9M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
DMA
XLO
Price
$7.06
$8.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $18.00
AVG Volume (30 Days)
★ 25.6K
14.4K
Earning Date
01-01-0001
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$23.90
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 589.88
52 Week Low
$6.94
$0.46
52 Week High
$9.15
$23.49

Technical Indicators

Market Signals
Indicator
DMA
XLO
Relative Strength Index (RSI) 34.18 50.12
Support Level $6.94 $7.29
Resistance Level $7.72 $9.35
Average True Range (ATR) 0.11 0.74
MACD 0.01 0.08
Stochastic Oscillator 31.25 71.00

Price Performance

Historical Comparison
DMA
XLO

About DMA Destra Multi-Alternative Fund

Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income, with an emphasis on income generation. The Fund pursues its investment objective by investing mainly in the income-producing securities of real estate investment trusts (REITs) and alternative investment funds, as well as common stocks and structured notes, bonds, and asset-backed securities.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: